K T

Death rate of wild-type and mutant tumor cells due to chemotherapy

( 8.1 × 10 1 ) X

day−1

[25] , [32]

K A T

Chemotherapy-induced death rate of wild-type and mutant tumors due to mAbs cetuximab and panitumumab

4 × 10 4

L mg−1 day−1

[32]

δ T

Chemotherapy efficacy coefficient on wild-type and mutant cancer cells

2 × 10 1

L mg−1

[32]

Y

Determines the percent level of the maximum rate of mAb-induced tumor death of wild-type and mutant cells

0.75

unitless

[32]

ψ

Rate of mAb-induced wild-type and mutant tumor cell death

( 2.28 × 10 2 ) Y

for cetuximab

( 3.125 × 10 2 ) Y

for panitumumab

L mg−1 day−1

[32]

f

Rate of NK cell turnover

1 × 10 2

day−1

[32]

e

Rate of NK synthesis from circulating lymphocytes

1 9 f

day−1

[32]

g N

IL-2 concentration needed for half-maximal NK cell proliferation

2.5036 × 10 5

IU L−1

[32]

p N

Rate of IL-2-induced NK cell proliferation

5.13 × 10 2

day−1

[32]

p

Rate of NK cell death due to interaction with the tumor

5.156 × 10 14

cell−1 day−1

[32]

p A

Rate of NK cell death due to interaction with mAbs complexes

6.5 × 10 10

(0 for panitumumab)

cell−1 day−1

[32]

K N

Rate of NK cell depletion due to chemotherapy toxicity

9.048 × 10 1

day−1

[32]

δ N

Coefficient of chemotherapy toxicity on NK cells

2 × 10 1

L mg−1

[32]

m

Rate of turnover of activated CD8+ T cells

5 × 10 3

day−1

[32]

θ

IL-2 concentration required to halve the CD8+ T cell turnover rate

2.5036 × 10 3

IU L−1

[32]

q

Rate of CD8+ T cell death due to interaction with the tumor

5.156 × 10 17

cell−1 day−1

[32]

r 1

Rate of activation of CD8+ T cell due to NK cell-lysed tumor cell debris

5.156 × 10 12

cell−1 day−1

[32]

r 2

Rate of CD8+ T cell production from circulating lymphocytes

1 × 10 15

cell−1 day−1

[32]